Sun Pharmaceutical Industries Dirección
Dirección controles de criterios 4/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Dilip Shanghvi
Chief Executive Officer (CEO)
₹60.5m
Compensación total
| Porcentaje del salario del CEO | 75.6% |
| Permanencia del CEO | 31.7yrs |
| Participación del CEO | 9.6% |
| Permanencia media de la dirección | 2.8yrs |
| Promedio de permanencia en la Junta Directiva | 3.5yrs |
Actualizaciones recientes de la dirección
Recent updates
Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
Nov 18
Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Oct 31We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease
Oct 21Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now
Aug 24Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next
Aug 06This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid
Jul 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth
Jun 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Jun 12Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 25Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings
May 22Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Mar 13Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Feb 03Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today
Jan 05Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely
Dec 18Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?
Oct 04Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?
Jul 03We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease
Jun 15Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?
Mar 14Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.50
Feb 03These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well
Dec 09Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?
Oct 13These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely
Sep 04Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Aug 05Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹111b |
| Jun 30 2024 | n/a | n/a | ₹104b |
| Mar 31 2024 | ₹61m | ₹46m | ₹96b |
| Dec 31 2023 | n/a | n/a | ₹89b |
| Sep 30 2023 | n/a | n/a | ₹85b |
| Jun 30 2023 | n/a | n/a | ₹84b |
| Mar 31 2023 | ₹55m | ₹41m | ₹85b |
| Dec 31 2022 | n/a | n/a | ₹42b |
| Sep 30 2022 | n/a | n/a | ₹41b |
| Jun 30 2022 | n/a | n/a | ₹39b |
| Mar 31 2022 | ₹51m | ₹38m | ₹33b |
| Dec 31 2021 | n/a | n/a | ₹64b |
| Sep 30 2021 | n/a | n/a | ₹62b |
| Jun 30 2021 | n/a | n/a | ₹60b |
| Mar 31 2021 | ₹46m | ₹35m | ₹29b |
| Dec 31 2020 | n/a | n/a | ₹24b |
| Sep 30 2020 | n/a | n/a | ₹15b |
| Jun 30 2020 | n/a | n/a | ₹7b |
| Mar 31 2020 | ₹43m | ₹32m | ₹38b |
| Dec 31 2019 | n/a | n/a | ₹40b |
| Sep 30 2019 | n/a | n/a | ₹43b |
| Jun 30 2019 | n/a | n/a | ₹30b |
| Mar 31 2019 | ₹263k | ₹1 | ₹27b |
| Dec 31 2018 | n/a | n/a | ₹34b |
| Sep 30 2018 | n/a | n/a | ₹24b |
| Jun 30 2018 | n/a | n/a | ₹36b |
| Mar 31 2018 | ₹34m | ₹28m | ₹21b |
Compensación vs. Mercado: La compensación total de Dilip($USD717.00K) está por debajo de la media de empresas de tamaño similar en el mercado Indian ($USD1.10M).
Compensación vs. Ingresos: La compensación de Dilip ha sido consistente con los resultados de la empresa en el último año.
CEO
Dilip Shanghvi (69 yo)
31.7yrs
Permanencia
₹60,541,920
Compensación
Mr. Dilip Shantilal Shanghvi serves as MD at Sun Petrochemicals Private Limited. He serves as Chairman of Board of Directors of Taro Pharmaceutical Industries Ltd at Taro Pharmaceuticals U.S.A., Inc. He se...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| MD & Chairman of the Board | no data | ₹60.54m | 9.6% ₹ 413.6b | |
| Executive VP | no data | ₹68.75m | 0.12% ₹ 5.2b | |
| Chief Financial Officer | 7.4yrs | ₹38.89m | sin datos | |
| Executive Vice-President of Global Operations | no data | sin datos | sin datos | |
| EVP & Chief Information Officer | less than a year | sin datos | sin datos | |
| VP, Head of Investor Relations & Strategic Projects | no data | sin datos | sin datos | |
| Company Secretary & Compliance Officer | 2.8yrs | sin datos | sin datos | |
| Director of Corporate Development | no data | ₹65.30m | sin datos | |
| Chief Human Resources Officer | less than a year | sin datos | sin datos | |
| Head of India Business | no data | sin datos | sin datos | |
| Chief Executive Officer of North America Business | 8.3yrs | sin datos | sin datos | |
| Head of Corporate Relations & CSR - India Regulatory Affairs | no data | sin datos | sin datos |
2.8yrs
Permanencia media
60yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de SUNPHARMA se considera experimentado (2.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| MD & Chairman of the Board | 31.7yrs | ₹60.54m | 9.6% ₹ 413.6b | |
| Executive VP | 1.4yrs | ₹68.75m | 0.12% ₹ 5.2b | |
| Non-Executive & Non-Independent Director | 30.8yrs | ₹2.20m | 1.8% ₹ 77.5b | |
| Non-Executive & Independent Director | 3.5yrs | ₹5.10m | sin datos | |
| Non-Executive Independent Director | 6.5yrs | ₹7.80m | sin datos | |
| Independent Director | 1.4yrs | ₹3.20m | sin datos | |
| Lead Independent Director | 3.5yrs | ₹8.50m | sin datos | |
| Independent Director | 2yrs | ₹4.80m | sin datos |
3.5yrs
Permanencia media
67.5yo
Promedio de edad
Junta con experiencia: La junta directiva de SUNPHARMA se considera experimentada (3.5 años de antigüedad promedio).